Zontivity
Product Images NDC 70347-208

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Zontivity (NDC 70347-208). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aralez Pharmaceuticals Us Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Zontivity 01)

FDA Label Image

Chemical Structure (Zontivity 02)

FDA Label Image

Figure 2 (Zontivity 03)

Figure 2 (Zontivity 03)
This appears to be a medication chart or table containing information about recommended doses and adjustments based on certain factors such as renal impairment or race. The table also includes a graph showing the recommended dosage for different time periods.*
FDA Label Image

Figure 3 (Zontivity 04)

Figure 3 (Zontivity 04)
This is a list of medications. The first two are antacids, one being Gaviscon in an extra-strength liquid form, and the other is a Proton Pump Inhibitor called Pantoprazole in a 0mg dose. Another medication listed is Prasugrel in a 10mg dose. The text mentions a "Moan Effectand 30% C1 Dose Adjustment" but does not provide further context. The text also includes instructions to avoid using certain medications concurrently and indicates that some items listed are not needed. Lastly, there is a numerical sequence of "00 05 1o 1 20 25" and a note to change "Rt to etrence [& A 5G]".*
FDA Label Image

Figure 4 (Zontivity 05)

FDA Label Image

Figure 5 (Zontivity 06)

Figure 5 (Zontivity 06)
This is a statistical representation of the incidence rates of the placebo versus ZONTIITY over a 24-month period. The data is presented in the form of a table with time intervals and number of patients at risk at each interval. The incidence of ZONTIMITY is 10.1%, which is lower than the placebo incidence of 11.8%. It also shows hazard ratios, 95% confidence intervals, and P-values.*
FDA Label Image

Figure 6 (Zontivity 07)

FDA Label Image

Principal Display Panel (30 Tablet Bottle Label)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.